300mg seroquel xr — no rx online. Quetiapine is an antagonist at both serotonin 5-HT2 and dopamine D2 receptors, and its antipsychotic effects are thought to stem from interactions at these receptors ...

Seroquel XR (quetiapine fumarate, from AstraZeneca) extended-release tablets have been launched in two new strengths, 50mg and 150mg.

SEROQUEL XR was launched for the treatment of schizophrenia in the US in 2007, and clinical development programs and regulatory filings are planned for a number of other indications.

AstraZeneca's Seroquel XR (quetiapine fumarate extended-release tablets) has been approved for the treatment of depressive episodes in bipolar disorder, manic and mixed episodes in bipolar I ...

LONDON, Nov. 13, 2008-AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved ...

LONDON (MarketWatch) -- AstraZeneca said Thursday that the European Commission has issued a positive decision for the approval of its Seroquel XR extended release tablets as an add-on treatment of ...

Earlier this month, AstraZeneca submitted an application for Seroquel XR tablets to treat generalized anxiety disorder, including maintenance of the anti-anxiety effect.

AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR (TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily ...

Seroquel XR extended-release tablets also contain black-box warnings because of an increased mortality rate in elderly patients with dementia. XR is indicated for the treatment of schizophrenia, a ...

Under the settlements, Accord and Handa agreed not to dispute AstraZeneca's patents covering Seroquel XR, and both companies will be able to launch generic versions of the drug in November 2016 ...

AstraZeneca today announced it has entered into a settlement agreement in its US SEROQUEL XR® patent infringement litigation against Handa Pharmaceuticals, LLC ("Handa") regarding Handa's ...